Idarubicin

Chemical formula: C₂₆H₂₇NO₉  Molecular mass: 497.494 g/mol  PubChem compound: 42890

Therapeutic indications

Idarubicin is indicated for:

Acute myeloid leukaemia (AML)

Population group: only adults (18 years old or older)

For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute myeloid leukaemia (AML)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute lymphoblastic leukaemia (ALL)

Population group: only adults (18 years old or older)

For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute lymphoblastic leukaemia (ALL)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Idarubicin is contraindicated in the following cases:

Persistent myelosuppression

Myelosuppression

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe cardiomyopathy

Cardiomyopathy

Uncontrolled infections

Infectious disease

Recent myocardial infarction

at least one of
Recent myocardial infarction
Myocardial infarction

Severe arrhythmias

Arrhythmia

Hypersensitivity to idarubicin

Idarubicin allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: ZAVEDOS Capsules
Summary of Product Characteristics (SPC) 2018: ZAVEDOS Powder for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈